GLP-1 medicines: what are they, and are Ozempic and Mounjaro the same?

14 sources · Latest source check 2026-10-15 UTC

On this page

GLP-1 receptor agonists mimic a gut hormone involved in blood-glucose regulation and appetite. Tirzepatide activates both GIP and GLP-1 receptors, making it a dual-incretin agonist. Benefits and approvals belong to particular products, doses, populations and outcomes.[1][2]

What does this actually mean?

The meaning

GLP-1 is a natural hormone signal involved in appetite and blood-sugar regulation. A GLP-1 receptor agonist is a medicine that activates the receiving part of that signal system. Agonist means a receptor activator. The nickname “GLP-1” is often used for a wider family of medicines, but the exact ingredient and product still matter.[11]

The familiar names

Ozempic and Wegovy both contain semaglutide, but a shared ingredient does not make their approved uses, formulations or instructions identical. Mounjaro and Zepbound contain tirzepatide, a different ingredient. Country matters too: a brand name in an online conversation is insufficient information to identify the product someone was actually prescribed.[10][5][11]

The important distinction

Semaglutide activates GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors, so it is called a dual-incretin medicine. Incretins are gut-hormone signals involved in glucose regulation. These names explain a mechanism; they do not rank every product, predict an individual’s response or establish that a treatment is suitable for everyone.[12]

What the evidence can tell you

Weight, blood glucose, heart attacks and sleep-apnea outcomes are different questions. A favorable result in one group cannot automatically answer another. The Wegovy HD announcement, for example, concerns a particular higher-dose product and adult weight-management indication. It does not provide a conversion rule for an Ozempic pen or another formulation.[4]

What the nickname leaves out

These treatments can have unwanted effects, ongoing costs and a need for continuing follow-up. NIDDK describes treatment choice as a shared decision that considers other conditions, medicines, tolerance, preferences and access. Reaching a weight goal is not itself evidence that a drug’s effects will persist after it is withdrawn.[12]

What to check

Before comparing offers, identify the ingredient, brand, route, strength, approved indication and dispensing pharmacy. Ask what outcome the proposed treatment is intended to improve and how follow-up works. Read the compounded-medicines explainer when an offer uses “custom,” “generic” or “compounded” language.[11]

The ingredient, brand, formulation and dose all matter

The cited Ozempic injection label includes pens delivering 0.25, 0.5, 1 or 2 mg semaglutide. These strengths are not a dose-conversion guide.[3]

SELECT tested injectable semaglutide 2.4 mg weekly. Its results belong to that studied regimen and population.[6]

FDA approved 7.2 mg Wegovy HD for certain adults’ weight management in March 2026. This is a separate dose and indication, not an instruction to escalate another product.[4]

An approved use is a specific regulatory statement

The cited US Ozempic label covers adult type 2 diabetes glucose control, cardiovascular-event reduction with established cardiovascular disease, and kidney-related outcomes with chronic kidney disease. Those indications are distinct from weight-management approval.[3]

EU Wegovy weight-management eligibility includes adults and selected adolescents from age 12. Its tablets are for adults; injections include eligible adolescents. Formulations and eligibility vary by jurisdiction.[5]

The US tirzepatide OSA indication concerns moderate to severe obstructive apnea in adults with obesity. This is not approval for every apnea type or population.[2]

Clinical events are different from an improved marker

SELECT found fewer major cardiovascular events than placebo in established cardiovascular disease with overweight or obesity, without diabetes. Randomized event evidence directly addresses this question, rather than observational longevity associations or a marker alone.[6]

Semaglutide’s MASH approval used biopsy improvement, with clinical confirmation ongoing. Histological and cardiovascular outcomes are distinct evidence questions.[7]

Benefits need a product-specific safety assessment

Common adverse effects include gastrointestinal symptoms. The cited semaglutide label includes warnings about pancreatitis, gallbladder disease, dehydration-related kidney injury, retinopathy complications and increased hypoglycemia risk when combined with insulin or insulin-secretagogue medicines. Its thyroid C-cell tumor warning comes from rodents; human risk is not established, and specific contraindications apply. Procedures, other medicines and relevant conditions need review.[3]

Safety information changes: in January 2026 FDA requested removal of suicidal-behavior and ideation warnings from affected weight-management products after its review found no increased risk. Dated approval announcements may still display the earlier wording.[1]

Treatment effects may not persist unchanged after stopping

In the STEP 1 extension, participants regained a substantial part of prior weight loss in the year after semaglutide and structured lifestyle support were withdrawn. This was an exploratory extension, not proof of the same trajectory for every person or product. Maintenance, tolerability, access and the consequences of discontinuation are part of the evidence question.[8]

Compounded and experimental products are different evidence questions

FDA states that compounded products are not FDA approved or premarket reviewed for safety, effectiveness and quality. It reports dosing errors and notes that semaglutide salt forms differ from the active ingredient in approved products. The current agency page identifies retatrutide and cagrilintide as unapproved ingredients. Evidence for an approved product cannot simply be transferred to an online vial labeled research use.[9]

Evidence & uncertainty

Some indications still require clinical-outcome confirmation. Product-specific evidence matters; this dated educational overview is not a prescribing or dose-conversion guide.[7]

Selected-source overview · Independent review pending

Published questions

Is tirzepatide the same mechanism as semaglutide?

Selected-source overview · Independent review pending. Read the evidence context.

Semaglutide activates GLP-1 receptors; tirzepatide activates both GIP and GLP-1 receptors. They are related but distinct medicines.[2]

Evidence behind this answer

FDA Approves First Medication for Obstructive Sleep Apnea
agency explanation · 2024-12-20
Selected page text; cited sections · Dual GIP/GLP-1 mechanism and OSA indication